Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
Download pdf
Abstract/Description: | The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following functional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment. |
---|---|
Subject(s): | 514/12.1 530/350 |
Date Issued: | 2012-07-03 |
Title: | Modified plasminogen activator inhibitor type-1 molecule and methods based thereon. |
|
---|---|---|
Name(s): |
The University of Toledo, assignee Jankun, Jerzy, inventor Skrzypczak-Jankun, Ewa, inventor Selman, Steven H., inventor |
|
Type of Resource: | text | |
Genre: | patent | |
Publisher: | United States Patent and Trademark Office | |
Other Date: | Date Filed: 2008-04-24 | |
Date Issued: | 2012-07-03 | |
Physical Form: | application/pdf | |
Extent: | 65 p. | |
Abstract/Description: | The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following functional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn); and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment. | |
Identifier(s): |
utpatents-US8211858 (IID) Patent No.: US8211858 (patno) Appl. No.: 12/597686 (appno) |
|
Subject(s): |
514/12.1 530/350 |
|
Held by: | United States Patent and Trademark Office (USPTO) Public Search Facility | |
Location: | University of Toledo Digital Repository | |
Rights Statement: | No Copyright - United States | |
In Collections: |